Rhodia structure gets a revamp

12 November 2001 00:00  [Source: ICB]

Rhodia has reinforced its paracetamol (acetaminophen) and aspirin (acetylsalicylic acid) businesses in order to strengthen its competitive position and better fulfil the needs of its pharmaceutical ingredients customers worldwide.

Rhodia has formed a new joint venture, Rhodia Wuxi Pharmaceutical, through the acquisition of a majority of the existing paracetamol operation of Wuxi Shahne Group No 1 Pharmaceutical, located in the Jiangsu province of China.

In addition, Rhodia has acquired BASF's paracetamol business, Rhodia assumes ownership of the business and related intellectual property and some specific equipment. Ownership of the Bishop, Texas, US, plant remains with BASF. Rhodia will ensure a seamless transition for its new clients with paracetamol from its Luling, Louisiana, US site.

Rhodia will consolidate aspirin production at sites in Saint Fons, France, and Bangpoo, Thailand, and cease production in St Louis, Missouri, US, to adjust capacity to demand levels and improve competitiveness. Production in St. Louis will continue until near the end of next year.

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly